Haisco's Record-Breaking License-Out: A Watershed Moment for Global Valuation of China's Innovative Drugs

Haisco’s License-Out Milestone: A “Watershed Moment” for Revaluing China’s Innovative Drugs on the Global Stage

In Q2 2024, Haisco Pharmaceutical Group Co., Ltd. (SZSE: 002653) announced two landmark overseas licensing deals: its self-developed, selective Nav1.8 inhibitor HSK-29116 was licensed globally to AbbVie, with an upfront payment of USD 30 million, potential milestone payments totaling up to USD 1.08 billion, and double-digit tiered royalties; combined with an earlier USD 108 million licensing agreement for a novel central nervous system (CNS) therapeutic with South Korea’s Daewoong Pharmaceutical, the company recognized over USD 130 million in licensing-related revenue in a single quarter. This breakthrough far exceeded market expectations—not only setting a new record for the highest upfront payment ever secured by a China-developed small-molecule innovative drug, but also marking a pivotal transition for Chinese biotech companies from the “technology validation phase” into a new era of “scalable value realization.” This shift is underscored by three dimensions: (1) target-level significance—Nav1.8 is widely regarded as the “holy grail target” in pain therapeutics; (2) clinical data quality—Phase II results demonstrated statistically significant superiority over placebo in patients with moderate-to-severe neuropathic pain, alongside favorable tolerability; and (3) transactional comprehensiveness—the deal covers full global rights and includes an equity collaboration clause.

Target Competitiveness + Clinical Execution: The Foundational Logic Behind Global Recognition

AbbVie’s decision is not an isolated event—it reflects a systematic endorsement of Haisco’s underlying R&D capabilities. Nav1.8 (a voltage-gated sodium channel subtype) is selectively expressed in peripheral sensory neurons and plays a critical role in pain signal transmission. Its inhibition blocks ascending nociceptive signaling while avoiding central nervous system (CNS) side effects—thanks to limited blood–brain barrier penetration. To date, no Nav1.8 inhibitor has gained regulatory approval globally; major pharmaceutical players—including Pfizer and Johnson & Johnson—have struggled for years with off-target toxicity or insufficient efficacy. Leveraging structure-based drug design, Haisco achieved exceptional selectivity (>1,000-fold over homologous targets such as Nav1.7 and Nav1.5) and optimized pharmacokinetic properties. Phase II data showed that in patients with diabetic peripheral neuropathy (DPN), the 300 mg dose of HSK-29116 reduced mean pain scores by 2.8 points versus placebo (p < 0.001), with no notable cardiovascular or CNS safety signals observed. This combination of “first-in-class potential” and a robust clinical evidence package represents precisely the kind of strategic asset that Big Pharma urgently seeks amid its current pipeline drought. Notably, the agreement includes a strategic equity investment by AbbVie in Haisco—signaling recognition not merely of a single asset, but of the Chinese team’s sustained capability to overcome historically “undruggable” targets.

Maturation of Business Development (BD) Capabilities: A Paradigm Shift from “Passive Engagement” to “Proactive Architecture”

Haisco’s transaction also reflects a qualitative leap in domestic biotech BD capabilities. Historically, license-out deals relied heavily on overseas CROs or intermediaries, often resulting in geographically restricted terms or excessive relinquishment of rights. By contrast, this collaboration was fully led by Haisco—from global rights valuation and clinical development pathway design to negotiation of risk-sharing mechanisms—culminating in a sophisticated three-dimensional structure: (1) unrestricted global licensing, (2) joint development, and (3) equity linkage. Crucially, the agreement explicitly reserves all rights in Greater China to Haisco, empowering it to lead local registration and commercialization, while entitling it to substantial royalties on AbbVie’s global sales. This marks a decisive departure from early-stage “selling green shoots” transactions toward deep, long-term value co-creation. According to industry BD insiders, Haisco’s team accurately anticipated AbbVie’s strategic need to bolster its pain portfolio during due diligence—and proactively strengthened its case with Asian-patient efficacy data and compelling evidence of scalable manufacturing processes. Such precision underscores Haisco’s attainment of professional parity with multinational pharma in strategic dialogue.

Systemic Revaluation Across the Entire Value Chain: Implications for CDMOs, ETFs, and the HKEX 18A Biotech Sector

The Haisco case will trigger a systemic revaluation of China’s innovative drug ecosystem across capital markets.

First, the CDMO sector’s logic is evolving: Investors are shifting focus from mere order volume toward assessing capacity to enable high-value assets. Leading CDMOs capable of supporting first-in-class molecules—from preclinical through pivotal Phase II data generation (e.g., WuXi AppTec, Asymchem)—will command premium valuations based on their technological moats and client stickiness. Meanwhile, low-cost capacity providers face increasing pressure to differentiate—or risk marginalization.

Second, innovative drug ETF allocation logic is being restructured: Current mainstream ETFs remain overweight in popular modalities like PD-1 inhibitors and ADCs. Yet Haisco demonstrates that “less-explored targets + rigorous clinical execution” can deliver explosive value. Going forward, fund managers may increasingly prioritize holdings with differentiated pipelines (e.g., Nav1.8, TRPV1, PDE4B) and mature BD capabilities—driving ETF portfolios toward deeper technical specialization.

Third, valuation anchors for HKEX 18A biotechs are shifting: Historically, valuations leaned heavily on clinical progress timelines or fundraising capacity. Haisco’s USD 1-billion-scale deal—secured solely on Phase II data—validates clinical data quality, rather than sheer pipeline breadth, as the harder, more reliable valuation cornerstone. 18A-listed firms possessing genuine clinical advantages (e.g., Hengrui’s SHR-8068, Innovent’s IBI-322) and in-house BD teams stand poised for upward valuation re-rating.

“Certainty Breakthrough” Amid Geopolitical Shadows: The Unique Resilience of Innovative Drug Licensing

Notably, even as geopolitical risks—including the Iran nuclear issue and tensions over the Strait of Hormuz—continue to disrupt global supply chains and capital flows, China’s innovative drug exports are achieving counter-cyclical breakthroughs. This resilience stems from the inherently apolitical nature of pharmaceutical licensing: such deals rest on scientific consensus and clinical value—not political alignment. Whether negotiations between the U.S. and Iran intensify over uranium enrichment rights or maritime sovereignty in the Strait (e.g., the Iranian Revolutionary Guard’s explicit red line prohibiting foreign warships), global pharmaceutical companies’ demand for effective therapies remains fundamentally inelastic. Haisco’s success thus affirms a broader truth: in an era of escalating uncertainty, truly irreplaceable medical innovations become safe havens—“certainty anchors” for both capital and industry. This “science-over-geopolitics” resilience may well attract renewed international investor interest in the long-term strategic allocation value of China’s biotech sector.

Conclusion: From “Catcher-Up Narrative” to “Value Definer”—A Critical Inflection Point

Haisco’s license-out is not an isolated event—it is the inevitable culmination of a decade of accumulated capability across China’s innovative drug industry. When target selection, clinical trial design, and BD architecture converge into a seamless, self-reinforcing loop, domestic biotechs transcend the role of “filling domestic gaps” and begin actively shaping global solutions for unmet medical needs. Markets must move beyond the outdated paradigm of “China-made = low-cost alternative,” and instead adopt “global clinical value contribution” as the primary metric for valuation—reassessing enterprises that hold differentiated targets, possess robust Phase II data, and demonstrate autonomous global commercialization capacity. This value re-rating, ignited by Haisco, will ultimately redefine China’s innovative pharmaceuticals on the global healthcare map: transforming them from rule-takers into value-definers.